Antibiotic Resistant Salmonella Typhimurium Emerges in Africa
|
By LabMedica International staff writers Posted on 14 Dec 2009 |
A new multi drug resistant strain of Salmonella typhimurium is causing life-threatening disease in Africa.
Genetic changes in the organism transformed this infection into a new antibiotic-resistant form of the disease. The new strain, called ST313, appears to be better adapted to affect humans, is resistant to several commonly used antibiotics, and may spread from person to person.
A team of scientists studied approximately 50 samples of the bacterial DNA, extracted from blood samples of African patients with severe symptoms of infection and suffering from HIV, malaria, malnutrition, or anemia. They used these samples to produce a high-quality reference genome sequence. Based on this sequence, the team was able to look in fine detail at the genetic differences between ST313 and strains associated with milder disease symptoms across the globe.
The severe effects of ST313--invasive disease and high mortality rates--are seen predominantly in individuals with the immune compromising conditions, HIV, malaria, malnutrition, or anemia. It had been assumed that this wasn't a new deadly form of the organism but, rather, that the existing diarrhea causing strain of the pathogen was taking advantage of the weakened immune system of patients with underlying health problems to cause a more severe disease.
"When we started looking in detail at our newly completed reference genome sequence, we saw the genetic signatures that suggested it might be adapting to humans," explained Dr Robert Kingsley from the Welcome Trust Sanger Institute (Cambridge, UK). "For example, this deadly strain has lost around one in 50 of the genes found in the 'typical' S. typhimurium--a classic sign that it may be becoming more closely adapted to one host, in this case, humans."
The scientists also found patterns of genome degeneration. Six out of 10 of the regions that showed degradation in the invasive ST313 are also degraded in S. typhimurium, suggesting that the genomes have converged in their ability to thrive in the human host. This theory is supported by the finding that eroded areas of the genome tend to play important roles in the intimate interaction with cells of the human host.
The team's findings suggest that ST313 may be spreading by a new method, not seen before in S. typhimurium. The pathogen normally circulates among animals and it is introduced to humans through food poisoning. It spends much of its time in the animal hosts. However, ST313 may be passing predominantly from person to person and so can adapt more rapidly to its human hosts: it does not spend time acquiring mutations to help it thrive in the animal host; in fact, it may be losing them.
However, ST313 acquired a block of genes that make it resistant to the common antibiotics. The genes jumped into ST313 on a mobile genetic element called a transposon, bringing with it additional genes that make the strain more deadly.
The study was published in the December 8, 2009 edition of the journal Genome Research.
Related Links:
Welcome Trust Sanger Institute
Genetic changes in the organism transformed this infection into a new antibiotic-resistant form of the disease. The new strain, called ST313, appears to be better adapted to affect humans, is resistant to several commonly used antibiotics, and may spread from person to person.
A team of scientists studied approximately 50 samples of the bacterial DNA, extracted from blood samples of African patients with severe symptoms of infection and suffering from HIV, malaria, malnutrition, or anemia. They used these samples to produce a high-quality reference genome sequence. Based on this sequence, the team was able to look in fine detail at the genetic differences between ST313 and strains associated with milder disease symptoms across the globe.
The severe effects of ST313--invasive disease and high mortality rates--are seen predominantly in individuals with the immune compromising conditions, HIV, malaria, malnutrition, or anemia. It had been assumed that this wasn't a new deadly form of the organism but, rather, that the existing diarrhea causing strain of the pathogen was taking advantage of the weakened immune system of patients with underlying health problems to cause a more severe disease.
"When we started looking in detail at our newly completed reference genome sequence, we saw the genetic signatures that suggested it might be adapting to humans," explained Dr Robert Kingsley from the Welcome Trust Sanger Institute (Cambridge, UK). "For example, this deadly strain has lost around one in 50 of the genes found in the 'typical' S. typhimurium--a classic sign that it may be becoming more closely adapted to one host, in this case, humans."
The scientists also found patterns of genome degeneration. Six out of 10 of the regions that showed degradation in the invasive ST313 are also degraded in S. typhimurium, suggesting that the genomes have converged in their ability to thrive in the human host. This theory is supported by the finding that eroded areas of the genome tend to play important roles in the intimate interaction with cells of the human host.
The team's findings suggest that ST313 may be spreading by a new method, not seen before in S. typhimurium. The pathogen normally circulates among animals and it is introduced to humans through food poisoning. It spends much of its time in the animal hosts. However, ST313 may be passing predominantly from person to person and so can adapt more rapidly to its human hosts: it does not spend time acquiring mutations to help it thrive in the animal host; in fact, it may be losing them.
However, ST313 acquired a block of genes that make it resistant to the common antibiotics. The genes jumped into ST313 on a mobile genetic element called a transposon, bringing with it additional genes that make the strain more deadly.
The study was published in the December 8, 2009 edition of the journal Genome Research.
Related Links:
Welcome Trust Sanger Institute
Latest Molecular Diagnostics News
- New PCR Assay Supports Bundibugyo Ebola Outbreak Surveillance
- Plasma Protein Signature Predicts Lung Cancer Risk Up to Five Years Ahead
- Circulating Tumor DNA Testing Guides Chemotherapy, Reduces Relapse in Colon Cancer
- Researchers Uncover Distinct Chromosome Signature in Aggresive ALT Cancers
- Simple Cytogenetic Method Could Improve Classification of ALL Subtypes
- Blood-Based Assay Enables Noninvasive Monitoring of Sarcoma Immunotherapy Response
- Genomic Test Guides Chemotherapy Decisions in Early-Stage Breast Cancer
- Tumor Mutation Marker Helps Refine Lung Cancer Prognosis and Guide Therapy Selection
- Multi-Cancer Test Boosts Detection When Added to Standard Screening
- Blood-Based MRD Monitoring Supports Relapse Prevention in Leukemia
- Genomic Test Predicts Chemotherapy Benefit in Metastatic Prostate Cancer
- Blood Protein Markers Flag Multiple Sclerosis Risk Years Before Diagnosis
- Digital PCR Assays Support Surveillance of Bundibugyo Ebolavirus Outbreak
- Updated Guidance Prioritizes Stool-Based Colorectal Cancer Screening Tests
- Blood-Based Proteomic Test May Predict Treatment Response in Non-Small Cell Lung Cancer
- Position Statements Outline Evidence Standards for Multi-Cancer Detection Tests
Channels
Clinical Chemistry
view channel
Saliva-Based Test Detects Biochemical Signs of Sleep Loss
Acute sleep loss impairs cognition and motor skills, raising safety risks that resemble alcohol intoxication. Clinicians currently lack an objective biochemical test to determine when someone is dangerously... Read more
Simple Dual-Tau Blood Test Detects and Stages Alzheimer’s Disease
Alzheimer’s disease is typically confirmed and staged with positron emission tomography scans and cerebrospinal fluid testing, procedures that are costly and invasive. Broader access to minimally invasive... Read more
Alzheimer’s Blood Biomarkers Linked to Early Cognitive Differences Before Dementia
Blood-based screening for Alzheimer’s disease offers a noninvasive, lower-cost alternative to brain imaging or spinal fluid testing, yet its ability to flag the earliest cognitive changes has been unclear.... Read moreMolecular Diagnostics
view channel
New PCR Assay Supports Bundibugyo Ebola Outbreak Surveillance
Rapid identification of Ebola infections is essential to limit transmission and guide public health response, yet detection can be difficult when outbreaks involve rare variants. The current outbreaks... Read more
Plasma Protein Signature Predicts Lung Cancer Risk Up to Five Years Ahead
Lung cancer remains a leading cause of cancer death, and many cases are detected only after symptoms appear. Current screening programs largely target people with a history of smoking, leaving other at-risk... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read moreImmunology
view channelAptamer-Based Biosensor Enables Mutation-Resilient SARS-CoV-2 Detection
Rapid evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can undermine existing molecular diagnostics, especially when assays target small viral components. Double-antibody sandwich... Read more
Study Points to Autoimmune Pathway Behind Long COVID Symptoms
Long COVID leaves many SARS-CoV-2 survivors with persistent fatigue, cognitive issues, palpitations, and musculoskeletal pain for months or years. Estimates cited in new research suggest 4%–20% of infected... Read more
Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response
Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read morePathology
view channel
3D Spatial Multi-Omics Maps Intra-Tumor Diversity in Colorectal Cancer
Colorectal cancer remains a leading cause of cancer death, and clinical decision-making is complicated by marked intra-tumor heterogeneity. Conventional bulk sequencing averages molecular signals across... Read more
Blood-Based Method Tracks Gene Activity in the Living Brain
Real-time measurement of gene activity in the brain has been limited by assays requiring destructive tissue sampling. Tracking active genes could reveal how the body responds to environmental factors,... Read moreTechnology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read moreIndustry
view channel
Collaboration Advances ctDNA-Guided Development in Metastatic Colorectal Cancer
Natera, Inc. (Austin, TX, USA) and CytoDyn Inc. (Vancouver, WA, USA) announced a strategic collaboration focused on metastatic colorectal cancer (mCRC). Under the agreement, Natera will evaluate circulating... Read more








